---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-008326"
form_type: "8-K"
ticker: "INDP"
cik: "0001857044"
company_name: "Indaptus Therapeutics, Inc."
filed_at: "2026-02-27T23:59:59+00:00"
generated_at: "2026-05-15T23:11:33.993095+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 1.0
calibrated_materiality_score: 1.0
confidence: "high"
source: SEC EDGAR
---

# Indaptus stockholders approve proposals enabling David Lazar to obtain 96.4% control; board changes

## Summary
- Lazar purchased $6.0M of preferred stock; upon conversion, 111M common shares issuable, representing ~96.4% of fully diluted outstanding.
- Authorized common stock increased from 200M to 1B shares; reverse stock split authorized at ratio 1:2 to 1:199.
- Jerome Jabbour and Matthew McMurdo elected as directors; Mark Gilbert and Michael Newman resigned immediately after meeting.
- Stockholders approved stockholder action by written consent and issuance of common stock upon conversion of preferred stock.
- Lazar's nominees now constitute majority of nine-member board; company plans to pursue strategic transaction with target company.

## SEC filing metadata
- accession: 0001493152-26-008326
- form_type: 8-K
- ticker: INDP
- cik: 0001857044
- company_name: Indaptus Therapeutics, Inc.
- filed_at: 2026-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 1.0
- calibrated_materiality_score: 1.0
- confidence: high
- sec_items: 3.03, 5.07, 5.03, 5.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1857044/000149315226008326/0001493152-26-008326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1857044/000149315226008326/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-008326
- JSON: https://secwatch.observer/filing/0001493152-26-008326.json
- Plain text: https://secwatch.observer/filing/0001493152-26-008326.txt

## Source-grounded claims
- claim_id: 2618b546c3db3411591b70e73c959599191bd1b3
  claim: Indaptus Therapeutics, Inc.: Approved amendments to the Charter to increase authorized common stock to 1,000,000,000 shares and permit stockholder action by written consent (effective 2026-02-27).
  evidence_excerpt: stockholders of the Company approved amendments to the Company’s Charter to (i) increase the number of authorized shares of our common stock to 1,000,000,000 (one billion) shares, and (ii) permit stockholder approval by written consent in lieu of a meeting.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315226008326/0001493152-26-008326-index.htm
- claim_id: 39425ec7e3e69681dc0838e0405fe42b789366c6
  claim: Indaptus Therapeutics, Inc.: Amended Section 2.13 of the Bylaws to provide that stockholder action must be at a meeting and not by written consent, unless the Certificate of Incorporation provides otherwise (effective 2026-02-27).
  evidence_excerpt: upon filing of the Certificate of Amendment with the Secretary of State of Delaware, Section 2.13 of the Company’s Amended and Restated Bylaws shall be deemed to be amended as follows: “Unless otherwise provided in the Certificate of Incorporation, any action required or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special meeting of stockholders of the Corporation and may not be effected by any consent in writing by such stockholders.”
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315226008326/0001493152-26-008326-index.htm
- claim_id: b248296a519cdaa1c8e425f3ea74156585186ba1
  claim: Indaptus Therapeutics, Inc. underwent a change of control involving David E. Lazar (closed 2026-02-26).
  evidence_excerpt: greement (the “Purchase Agreement”) with David E. Lazar (“Mr. Lazar”) pursuant to which he purchased from the Company 300,000 shares of Series AA Convertible Preferred Stock (the “Series AA Preferred Stock”) and 700,000 shares of Series
  evidence_url: https://www.sec.gov/Archives/edgar/data/1857044/000149315226008326/0001493152-26-008326-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.